Curriculum Vitae
`Leslie Oleksowicz, M.D.
`
`Date Prepared:
`
`03/01/2022
`
`Name:
`
`Leslie Oleksowicz, M.D.
`
`Home Address:
`
`2627 Stonehaven Drive
`
`Phone:
`
`Email:
`
`Cincinnati, OH 45245
`
`HOME: 513-620-8685; Cell: 513-403-2650
`
`leslie.oleksowicz@gmail.com
`
`loleksowicz@earthlink.net
`
`Place of Birth &
`
`Ware, MA 01082
`
`Citizenship
`
`U.S Citizen
`
`Education
`9/1974 - 6/1978
`
`BA
`Magna Cum Laude
`Phi Beta Kappa
`9/1978 - 6/1982 MD
`
`Biology
`
`Medicine
`
`Amherst College
`Amherst, Massachusetts
`
`Tufts University School of Medicine
`Boston, Massachusetts
`
`Postdoctoral Training
`7/1982-7/1985
`Residency
`
`7/1985-7/1987
`7/1987-7/1989
`
`Fellowship
`Fellowship
`
`Current Employment
`
`Internal Medicine
`
`Hematology
`Medical Oncology
`
`Montefiore Hospital/ Albert Einstein College of
`Medicine, Bronx, New York
`Mount Sinai Medical Center, New York, New York
`Mount Sinai Medical Center, New York, New York.
`
`1/2015-present
`
`Leslie Oleksowicz, M.D, LLC, Consultant
`
`8190-A Beechmont Ave, Suite 175
` Cincinnati, OH 45255-6177
`
`Faculty Academic Appointments
`
`7/1989-11/1991
`6/1992-7/1998
`
`9/1998-7/2003
`
`9/2003-5/2012
`
`8/2012-4/2013
`
`9/16/2013-
`12/31/2014
`
`Instructor
`Assistant Professor of
`Medicine
`
`Associate Professor of
`Medicine
`Associate Professor of
`Medicine
`Professor of Medicine
`
`Medical Oncology
`Medical Oncology
`
`Medical Oncology
`
`Hematology/Oncology
`
`Hematology/Oncology
`
`Attending Clinician
`
`Hematology/Oncology
`
`Mount Sinai Medical Center, New York, New York
`Montefiore Hospital/ Albert Einstein College of
`Medicine
`Bronx, New York
`Roswell Park Cancer Institute
`Buffalo, New York
`University Hospital/University of Cincinnati
`Cincinnati, Ohio
`Saint Louis University Medical Center, Saint Louis,
`Missouri
`Dana Farber Cancer Institute
`Boston, Massachusetts
`
`1
`
`Rigel Exhibit 1006
`Page 1 of 16
`
`

`

`
`
`Appointments at Hospitals/Affiliated Institutions
`
`7/1989-11/1991 Clinical Assistant
`6/1992-7/1998
`Assistant Attending
`9/1998-7/2003
`Associate Attending
`9/2003-5/2012
`Associate Attending
`9/2003-5/2012
`Associate Attending
`
`Medical Oncology
`Medical Oncology
`Internal Medicine/Medical Oncology
`Internal Medicine/Medical Oncology
`Internal Medicine/Medical Oncology
`
`12/2004-6/2010 Courtesy Associate
`Attending
`Associate Attending
`
`9/2003-5/2012
`
`Internal Medicine/Medical Oncology
`
`Internal Medicine/Medical Oncology
`
`4/2009-5/2012
`
`Associate Attending
`
`Internal Medicine/Medical Oncology
`
`8/2012-4/2013
`9/2013-12/2014
`
`Attending Professor
`Faculty Clinician
`
`Internal Medicine/Medical Oncology
`Medical Oncology
`
`9/2013-12/2014 Clinician
`
`Hematology/Oncology
`
`New York (active)
`Ohio (active)
`Missouri (inactive)
`Connecticut (inactive)
`
`Current Licensure
`
`1985
`2003
`2012
`2013
` Certification
`
`Board Certified Diplomat in Internal Medicine
`10/1987
`Board Certified Diplomat in Medical Oncology
`8/1989
`Other Professional Positions
`1/1997-3/1997
`Consultant
`
`10/1996-3/1998
`
`Course Director
`
`Advisory Board Member
`Course Director
`
`8/2002-6/2012
`6/10/2006
`
`Course Director
`7/22/2006
`Advisory Board Member
`9/2007-9/2008
`Course Director
`7/2007-9/2008
`9/2007-9/2008 Member speaker bureau
`2/2008-5/2012
`Advisory Board Member
`7/26/2008
`Course Director
`8/2008-4/2013
`Principal Investigator of SWOG
`9/2009-10/2010 Advisory Board Member
`7/26/2009
`Course Director
`6/2011-6/2012
`Advisory Board Member
`Major Administrative Leadership Positions
`Local
`9/1998-7/2003
`9/1998-7/2003
`
`Director of GU Oncology
`Director of Melanoma and Sarcoma Oncology
`
`
`
`Mount Sinai Medical Center
`Montefiore Hospital
`Roswell Park Cancer Institute
`University Hospital, University of Cincinnati
`University Point Practice,
`Satellite facility of University of Cincinnati, West
`Chester, OH
`Christ Hospital, Cincinnati, OH
`
`West Chester Medical Center, West Chester, OH
`(hospital owned by University of Cincinnati)
`University Point Surgical Hospital, West Chester,
`OH
`Saint Louis University Hospital
`Dana Farber Cancer Institute
`Boston, MA
`Lawrence and Memorial/Dana Farber Community
`Cancer Center, Waterford, CT
`Lawrence and Memorial Hospital, New London, CT
`
`#158402-1
`#35-083335
`#2012021332
`#052051
`
`Roswell Park Cancer Institute
`Roswell Park Cancer Institute
`
`2
`
`
`Merck Pharmaceutical: Evaluation of clinical and laboratory data related to
`COX-2 inhibitor.
`Practical Reviews in Cancer Management. Monthly review of recent clinical
`studies in medical oncology
`
`National Kidney Cancer Association
`Mid-West Leukemia Symposium
`
`First Annual University of Cincinnati Genitourinary Symposium
`Novartis (Interleukin-2)
`Second Annual University of Cincinnati Genitourinary Symposium
`Bayer/Onyx
`Association of Community Cancer Center
`Third Annual University of Cincinnati Genito-Urinary Symposium
`University of Cincinnati and University of Saint Louis
`Pfizer
`Fourth Annual University of Cincinnati Genitourinary Symposium
`Centacore-Ortho
`
`Rigel Exhibit 1006
`Page 2 of 16
`
`

`

`
`Director of High Dose IL-2 Service
`9/1998-7/2003
`Director of GU Oncology
`7/2003-5/2012
`Director of Melanoma and Sarcoma Oncology
`7/2003-5/2012
`Director of High Dose IL-2 Service
`7/2003-5/2012
`Co-Director Leukemia Services
`11/2003-6/2009
`Director GU Services
`8/2012-4/2013
`Director of Melanoma/Sarcoma Services
`8/2012-4/2013
`
`
`
`
`
`
`Committee Service
`Local
`9/1992-6/1998
`
`Transfusion Committee
`9/92-6/1998
`Cancer Center Protocol Review Committee
`9/1995-6/1998
`Cancer Center Protocol Audit Committee
`9/1995-6/1998
`Hematology Malignancy Working Group
`9/1992-6/1998
`Breast Malignancy Affinity Group
`9/1992-6/1998
`CME Advisory Board
`10/1998-10/1999
`Morbidity and Mortality Committee
`5/1999-6/2000
`Quality Improvement Committee
`5/1999-6/2000
`IRB
`1/2001-1/2002
`Hematology/Oncology Grand Rounds
`9/2003-4/2012
`Scientific Review Protocol Committee
`9/2003-5/2006
`Ethics Committee
`9/2004-6/2006
`Hematology/Oncology Clinical Research Forum
`9/2003-8/2008
`LEUKEMIA Affinity Group
`9/2004-7/2007
`Medical Center Fund of Cincinnati
`5/2008-5/2012
`
`9/1995-6/1998
`
`9/1995-6/1998
`
`9/1992-6/1998
`
`9/1992-6/1998
`
`10/1998-10/1999
`
`5/1999-6/2000
`
`5/1999-6/2000
`
`1/2001-1/2002
`
`9/2003-4/2012
`
`9/2003-5/2006
`
`9/2004-6/2006
`
`9/2003-8/2008
`
`9/2004-7/2007
`
`5/2008-5/2012
`
`Regional
`1985-1987
`
`Society for the Study of Blood
`
`National and International
`11/002-11/2003 Advisory Board on Cancer Related Fatigue
`11/2002-11/2003
`Advisory board
`8/2002-present
`Professional Societies
`1/1990-9/2012
`American Society of Hematology
`1/1990-9/2003
`American Society of Clinical Oncology
`1996-present
`Cancer and Leukemia B (CALGB)
`
`8/2002-present
`
`1996-present
`
`9/1998-6/2003
`
`Roswell Park Cancer Institute
`University of Cincinnati Medical Center
`University of Cincinnati Medical Center
`University of Cincinnati Medical center
`University of Cincinnati Medical center
`University of Saint Louis Medical Center
`University of Saint Louis Medical Center
`
`
`
`
`Montefiore Hospital/Albert Einstein College of Medicine
`Member
`Albert Einstein Cancer Center
`Vice Chair
`Albert Einstein Cancer Center
`Coordinator
`Montefiore Hospital/Albert Einstein
`Member
`Member
`Montefiore Hospital/Albert Einstein
`Roswell Park Cancer Institute
`Member
`Roswell Park Cancer Institute
`Member
`Roswell Park
`Member
`Roswell Park
`Member
`University of Cincinnati
`Director, Coordinator and Master of Ceremonies
`University of Cincinnati
`Member
`University of Cincinnati
`Co-Chair
`University of Cincinnati
`Director
`University of Cincinnati
`Member
`University of Cincinnati
`Member
`
`Teaching Hospitals in the Greater New York Area
`Member
`
`NCCN
`Member
`National Kidney Cancer Association
`Member
`
`Member
`
`Member
`
`Member
`
`3
`
`
`Rigel Exhibit 1006
`Page 3 of 16
`
`

`

`6/1992-7/1998
`
`1985-present
`
`1982-1987
`
`9/1998-6/2003
`Eastern cooperative Group (ECOG)
`6/1992-7/1998
`Phi Delta Epsilon Fraternity
`1985-present
`American College of Physicians
`1982-1987
`
`8/2002-present
`
`National Kidney Cancer Association
`8/2002-present
`SWOG
`10/2003-4/2013
`Editorial Activities
`Cancer
`Transfusion
`Southern Journal of Medicine
`Journal of Urology
`American Journal of Medical Sciences
`Other Editorial Roles
`2009-present
`Editorial Advisory Board
`Honors and Prizes
`
`Member
`
`Member
`
`Member
`
`Member, Editorial Advisory Board
`
`Member
`
`Kidney Cancer
`
`Amherst College
`Tufts University School of Medicine
`Tuft University School of Medicine
`Albert Einstein college of Medicine
`
`6/1978
`9/1978-9/1982
`9/1978-9/1982
`2/1997
`
`Webster Prize
`Simpson Fellowship
`Hampden Scholarship
`Third Prize awarded at basic
`investigators research symposium
`11/2002
`Certificate of recognition
`Roswell Park
`Report of Funded and Unfunded Projects
`Funding Information
`Past
`
`Undergraduate Thesis
`Scholarship based on GPA
`Scholarship based on GPA
`Third prize for best scientific paper
`
`Excellence in clinical practice
`
`1/1999-6/2003
`
`1/1999-6/2003
`
`1/1999-6/2003
`
`1/1999-6/2003
`
`1/2003-6/2004
`
`04/2005-5/2006
`
`04/2005
`
`
`
`7/1992-7/1993
`7/1993-6/1996
`
`7/1993-6/1996
`7/1993-6/1996
`7/1994-4/1995
`
`7/1994-4/1995
`
`A Phase II Pilot Study of Dose –Intensive IL-2, DTIC and IFN in Patients with Metastatic Malignant Melanoma.
`Leslie Oleksowicz,: P.I.; $60,000 from Schering Pharmaceuticals
`A Phase II Study of Dose-Intensive IL-2 by IV Bolus and Low Dose Immunomodulating IFN as Therapy for Patients with
`Metastatic or Unresectable RCC. Leslie. Oleksowicz, P.I. Investigator-initiated. $40,000 from Schering
`Pharmaceuticals
`An adjuvant Dose-intensive Trial of High Dose bolus IL-2 in Patients with High Risk Renal Cell Carcinoma.
` Leslie. Oleksowicz, P.I. Investigator Initiated. $20.000 from Chiron Pharmaceuticals
`A Phase II Study of Post-Transurethral Resection M-VAC and Taxol/Gemcitabine Chemotherapy in Patients with
`Invasive Transitional Cell Bladder Cancer. Leslie Oleksowicz, P.I. $50,000 from Bristol Pharmaceuticals.
`A Phase II Trial Investigating the Efficacy of High Dose-Intensive IL-2 in Combination with Capecitabine in Patients
`with Stage IV Renal Cell Carcinoma. Leslie Oleksowicz, P.I. $75,000 from Roche Pharmaceuticals.
`A Phase II Trial of Fludarabine and High Dose Bolus Interleukin-2 in Patients with Stage IV or Surgically Unresectable
`Renal Cell Carcinoma. Leslie Oleksowicz, P.I. Investigator-initiated; $150,000 from Chiron.
`A Phase II Trial of Taxotere, Gleevec, Complete Androgen Blockade and Zometa in Patients with a Rising PSA s/p
`Definitive Treatment. Leslie Oleksowicz, P.I. Investigator-Initiated. $120,000 from Novartis
`
`
`The Role of IL-6 on Platelet Function. Leslie Oleksowicz, P.I. $20,000 from Sandoz Pharmaceuticals
`The Mechanisms of Anti-Tumor Activity of IL-2 and Il-6: The Relationships between the Hemostatic and Immune
`Systems. Leslie Oleksowicz, P.I.; $150,000 from American Cancer Society.
`The Role of IL-6 on Platelet Function. Leslie Oleksowicz, P.I. $60,000 from Sandoz Pharmaceuticals.
`Research in Platelet Function. Leslie Oleksowicz, P.I. $25,000 from Irving A Hansen Memorial Foundation.
`Impedance Agregometry Investigating Platelet Tumor Interactions. Leslie Oleksowicz, P.I., $30,000 from Carol Solar
`Abbani Foundation.
`Ex vivo Platelet Functional Studies in Patients with Advanced Breast Carcinoma Who have Undergone Autologous
`
`
`
`4
`
`Rigel Exhibit 1006
`Page 4 of 16
`
`

`

`Bone Marrow Transplantation and have been Treated with IL-6 or Placebo. Leslie Oleksowicz, P.I.; $30,000 from
`Sandoz Pharmaceuticals.
`Characterization of Immunorelated GPIb Expression by Myelogenous Leukemia Cells. Leslie Oleksowicz, P.I.,
`$30,000, National Leukemia Research Association.
`The Role of Tumor GPIbα in Platelet-Tumor Adhesive Interactions and Metastasis. Leslie Oleksowicz, P.I. $80,000
`from the Elsa U. Pardee Foundation.
`The Role of GP1b Expressed by Renal Carcinoma Cells in Primary Adhesive Interactions Required for the Metastatic
`Process. Leslie Oleksowicz: P.I., $30,000 from the Bruce Cuvelier Endowed Research Fund in Urology.
`Tumor Expression of the Immunorelated Platelet Adhesive receptor: GP1bα and α2β3: Novel Targets for Anti-
`Neoplastic Strategies. Leslie Oleksowicz: P.I. $50,000 from the Roswell Park Alliance Foundation.
`
`
`
`1/1996-12/1997
`
`7/1997-7/1998
`
`1/1999-1/2001
`
`11/1999-10/2000
`
`
`
`Additional Clinical Trials
`
`7/1992-7/1993
`
`5/1992-11/1993
`
`8/1993-10/1995
`
`7/1994-8/1995
`
`1/1994-1/1996
`
`10/1994-9/1998
`
`6/1996-11/1997
`
`7/1996-9/1997
`
`11/1996-2/1997
`
`7/1997-3/1999
`
`5/1997-6/1998
`
`7/1999-5/20000
`
`7/2002-6/2003
`
`7/2002-6/2003
`
`7/2002-6/2003
`
`2/2003-5/2003
`
`5/2002-7/2003
`
`9/2003-5/2006
`
`3/2004-11/2007
`
`11/2004-2/2006
`
`
`Co-Investigator: A Compassionate Study of High Dose IL-2 by I.V. Bolus in Patients with Metastatic or unresectable
`Renal Cell Carcinoma. Investigator-Initiated Trial.
`Co-Investigator: A Phase I Study of Interleukin-6 (IL-6, SDZ ILS 969) Administered by 120-Hour Continuous Intravenous
`Infusion. Sponsored by the Cytokine Working Group and Sandoz Pharmaceuticals
`Co-Investigator: Open-Label, Multicenter Trial of Actimmune Interferon Gamma-1b (IFN-γ1b) in Patients with
`Metastatic Renal Cell Carcinoma. Sponsored by Genentech.
`Co-Investigator: A Phase III Randomized Double Blind, Placebo-Controlled Study or CT-1501R and High Dose
`Intermittent Interleukin-2 in the Treatment of Patients with Advanced Renal Cell or Metastatic Malignant Melanoma.
`Sponsored by Cell therapeutics.
`Co-investigator: Chemo-Immunotherapy of Metastatic Renal Cell Carcinoma with IL-2, Interferon-α2b, and 5-FU.
`Sponsored by the Cytokine Working Group.
`Co-Investigator: Randomized Phase II Trial of Chemotherapy and Outpatient Biotherapy in Metastatic Malignant
`Melanoma. Sponsored by the Cytokine Working Group.
`Co-Investigator: A Multicenter Phase II Evaluation of Combination Therapy of Targretin Oral Capsules (LGD 1069) and
`Intron A in patients with Advanced Renal cell Carcinoma. Sponsored by Ligand Pharmaceuticals and the Schering
`Co-Investigator: A Phase II Study of Moderate Dose IL-2 by I.V. Bolus and Subcutaneous GM-CSF in Patients with
`Metastatic or unresectable Renal Cell Carcinoma. Investigator-initiated study.
`Co-Investigator: Open-Label Randomized, Dose-Escalating Study of Recombinant Human Interleukin-12 administered
`by sub-cutaneous Injection in Patients with Advanced Malignancies. Sponsored by Genetics Institute and Wyeth-
`Ayerst.
`Co-Investigator. A Randomized Phase III Trial of High-Dose IL-2 Versus Subcutaneous Interleukin-2/IFN in Patients with
`Metastatic Renal Cell Carcinoma. Sponsored by the Cytokine Working Group.
`Co-Investigator: Open-Label, Non-Randomized, Dose-Escalating Study of Recombinant Human Interleukin-12 by IV
`injection in Patients with Untreated or Previously Treated Advanced RCC. Sponsored by Genetics Institute and Wyeth-
`Ayerst.
`A Multi-Center, Escalating dose Phase I Study of IV DENSPM administer daily for 5 days as a Loading dose followed by
`thrice weekly maintenance dosing for two weeks. Sponsored by Parke-Davis.
`Co-Investigator. Phase I Study of Intravenous Tumor Necrosis Factor-alpha Plus Doxorubicin in Patients with Advanced
`Solid tumors. A Pilot Study.
`Co-Investigator. Phase I Study and Pharmacokinetics of Irinotecan in Combination with Fixed Dose Celecoxib in
`Patients with Advanced Colorectal Cancer. Instituion-sponsered trial.
`Co-Investigator. A Phase I Trial of Subcutaneous and Oral Calcitriol (1,25-(OH)2D3) & Carboplatin in Advanced Solid
`Tumors. Sponsored by Abbott, Hoffman-LaRoche, CapCURE.
`Principal Investigator. A Phase II Study of Capecitabine (IND #62761) Plus Gemcitabine for Metastatic Renal Cell
`Carcinoma. CALGB 9008.
`Principal Investigator. Multi-Center Randomized, Controlled, Double-Blind Parallel-Group Study to Compare the
`Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma whose Disease
`has progressed on Treatment with DTIC, IL-2, IFNα or IFNβ. Sponsored by Celgene.
`Co-Investigator. Prospective Phase II Clinical Trial: Interferon-alpha, Tamoxifen and Thalidomide for the Treatment of
`Advanced Renal Cell Carcinoma. Sponsored by Celgene.
`Co-Investigator. A Randomized Double Blind, Placebo Controlled Phase III Trial of Immunotherapy with Autologous
`Antigen-Presenting Cells Loaded with PA2024 (Provenge, APC8015) in Asymptomatic Subjects with Gleason Sum
`<7,Metastatic Androgen independent Prostate Cancer . Sponsored by Dendreon Corporation.
`Principal Investigator. Phase II Randomized, Open-Label, Three-Arm, Multicenter Study of Medi-522, A
`Humanized Monoclonal Antibody Directed against the αvβ3 Integrin, in Combination with Docetaxel, Prednisone and
`5
`
`
`Rigel Exhibit 1006
`Page 5 of 16
`
`

`

`11/204-6/2008
`
`3/2005-6/2008
`1/2005-1/2007
`
`7/2005-3/2006
`
`9/2005-6/2008
`12/2005-1/2007
`
`10/2006-9/2007
`
`5/2006-5/2007
`
`1/2005-5/2007
`
`5/2006-2/2020
`
`1/2007-2/2011
`
`1/2006-10/2009
`
`1/2006-9/2008
`7/2007-6/2009
`1/2007-10/2010
`
`2/2007-3/2010
`
`3/2008-7/2010
`
`1/2007-5/2009
`1/2007-1/2009
`
`8/2008-5/2012
`
`8/2008-9/2009
`
`8/2008-10/2010
`
`8/2008-5/2012
`
`10/2008-6/2009
`
`8/2009-7/2010
`
`10/2008-8/2010
`
`11/2008-7/2010
`
`5/2008-9/2010
`
`9/2008-5/2009
`
`8/2008-3/2009
`
`8/2008-6/2009
`
`Zolendronic acid in the Treatment of Patients with Metastatic Androgen Independent Prostate Cancer. Sponsored by
`Medimmune.
`Co-Investigator, Cytarabine and Daunorubicin with or without Gemtuzumab followed by HD Cytarabine and either
`Gemtuzumab in de Novo AML. SWOG S0106
`Co-Investigator. Lenalidomide in treating older patients with AML . S0605
`Principal Investigator: Clinical Protocol CA183001. A Phase II Study of I.V. Vinflunine in Patients with Locally Advanced
`or Metastatic Transitional Cell Carcinoma of the Urothelium. Bristol/Myers/Squibb.
`Principal Investigator: A Phase III Randomized Open-Label Study of CG1940 and CG8711 vs. Docetaxel and Prednisone
`in Patients with Metastatic Hormone Refractory Prostate Cancer who are Chemotherapy-Naïve. Sponsored by Cell
`Genesys.
`Cytarabine an Daunorubicin in treatinng older patients with AML. SWOG S0112
`Principal Investigator: SWOG 0508. Phase II Trial of Combination Thalidomide plus Temozolomide in Patients with
`Malignant Melanoma. SWOG-0508.
`Principal Investigator: Clinical Protocol CA184024. A Multicenter Randomized Double-Blind Two Arm Phase III Study in
`Patients with Untreated or Stage IV Melanoma Receiving DTIC plus 10 mg/kg Ipilimumb vs. DTIC with Placebo. BMS.
`Principal Investigator: SWOG 0306. A Phase II Study of Irinotecan in Patients with Advanced Transitional Cell
`Carcinoma of the Urothelium. SWOG 0306.
`Co-Investigator: Phase III trial of High Dose Interferon vs. Cisplatin, Vinblastine, DTIC plus IL-2 and Interferon in
`Patients with High Risk Melanoma.
`Co-Investigator: A Phase III Protocol of Androgen Suppression and 3DCRT/IMRT vs. AS and 3DCRT/IMRT Followed by
`Chemotherapy with Docetaxel and Prednisone for Localized High Risk Prostate Cancer. Sponsored by RTOG.
`Principal Investigator: ASSURE TRIAL. ECOG 2805. A Randomized Double Blind Phase II Trial of Adjuvant Sunitnib vs.
`Sorafinib vs. Placebo in Patients with Resected Renal Cell Carcinoma. Sponsored by ECOG 2805.
`Co-Investigator: SWOG 0512. Phase II trial of BAY 43-9006 (Sorafinib) in Combination with Carboplatin and Paclitaxel
`in Patients with Uveal Melanoma. SWOG 0512.
`Co-Investigator: SWOG 0505. Phase II trial of BAY 43-9006 in Advanced Soft Tissue Sarcoma. SWOG 0505.
`Principal Investigator: Lenalidomide in Treating Older patients with AML. SWOG
`Principal Investigator: A Randomized Double Blind Placebo Controlled Phase III study of Early vs. Standard Zolindronic
`Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to the Bones. CALGB 90202.
`Co-Investigator: SWOG 0421. Phase III study of Docetaxel and Altrasentan vs. Docetaxel and Placebo in Patients with
`Advanced Hormone Refractory Prostate Cancer. SWOG 0421.
`Principal Investigator: Multi-institutional Consortium: The High Dose Aldesleukin (IL-2) “SELECT” Trial in Patients with
`Metastatic Renal Cell Carcinoma. NOVARTIS.
`Principal Investigator: High Dose Interferon Alpha in Treating Patients with Stage II or Stage III Melanoma. SWOG.
`Principal Investigator: Androgen Ablation Therapy with or without Chemotherapy in Treating Patients with Metastatic
`Prostate Cancer. Intergroup Trial.
`Principal Investigator: Phase III Randomized Trial of Anastrozole vs. Anastrozole and Fulvestrant as First Line Therapy
`in Post-Menopausal Women with Metastatic Breast Cancer. SWOG 1222.
`Principal Investigator: Phase II Studies of Two Different Schedules of Dasatinib in Bone Metastasis Predominant
`Metastatic Breast Cancer. SWOG-0622.
`Principal Investigator: Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without Bevacizumab
`as Second line Therapy in Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with
`either FOLFOX, OPTIMOX or XELOX. SWOG-0600.
`Principal Investigator: A Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon alpha vs.
`Depot Octreotide plus Bevacizumab in Advanced Poor Prognosis Carcinoid Patients. SWOG-0518
`Principal Investigator: Gemtuzumab and Combination Chemotherapy in Treating Patients with Previously Untreated
`APL. SWOG.
`Principal Investigator: A Randomized Double Blind Placebo Controlled Phase III Study of Early vs. Standard Zeledronic
`Acid to Prevent Skeletal-Related Events in Men with Prostate Cancer Metastatic to Bone. SWOG 90202.
`Principal Investigator: Acetyl-Carnitine in Preventing Neuropathy in Women with Stage I, II or IIIA Breast Cancer
`Undergoing Chemotherapy. SWOG.
`Principal Investigator: Capecitabine, Gemcitabine and Radiation Therapy in Treating Patients with
`Cholangiocarcinoma of the Gallbladder or Bile duct. SWOG.
`Principal Investigator: Erlotinib and Bevacizumab in Treating Patients with Stage IIIb or Stage IV Primary Non-Small
`Cell Lung Cancers Who Have Never Smoked. SWOG.
`Principal Investigator: Cytogenetic Studies in Leukemia Patients, Ancillary SWOG 9007 and Leukemia Centralized
`Reference Laboratories and Tissue Repositories. Ancillary SWOG 9910.
`Principal Investigator: A Phase II Study of Lenalidomide for Previously Untreated Non-M3, Deletion 5q Acute AML in
`Patients age 60 or Older Who Decline Remission Induction Chemotherapy. SWOG 0605.
`Principal Investigator: A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for
`Previous Untreated Patients with CML in the Chronic Phase. SWOG 0325.
`
`6
`
`Rigel Exhibit 1006
`Page 6 of 16
`
`

`

`
`8/2008-6/2009
`
`8/2008-5/2023
`8/2008-5/2012
`
`8/2008-11/2009
`
`8/2008-10/2009
`
`7/2008-10/2009
`
`9/2008-5/2012
`
`8/2009-9/2011
`
`8/2009-9/2011
`
`11/2008-5/2010
`
`9/2008-11/2009
`
`2/2008-6/2010
`
`9/2008-5/2009
`
`9/2008-3/2011
`
`9/2009-8/2020
`
`4/2008-6/2009
`
`9/2009-5/2012
`6/2009-5/2012
`
`6/2009-5/2012
`
`8/2008-11/2010
`
`06/2009-7/2010
`
`6/2009-7/2010
`
`6/2009-5/2012
`
`6/2009-5/2012
`
`1/2009-3/2010
`
`6/2009-5/2012
`
`1/2009-3/2010
`
`4/2009-1/2012
`2/2009-4/2011
`6/2009-7/2010
`
`2/2012-5/2012
`
`10/2010-5/2012
`
`Principal Investigator: A Phase II Study of ATRA, Arsenic Trioxide and Gentuzumab Ozogamicin in Patients with
`Previously Untreated High Risk Acute Promyelocytic Leukemia. SWOG 0535.
`Principal Investigator: Lung Cancer Specimen Repository Protocol, Ancillary. SWOG 9925
`Principal Investigator: Phase III Chemo-Prevention Trial of Selenium Supplementation in Patients with Resected Stage
`I NSCLC. SWOG E5597.
`Principal Investigator: A Pilot Phase I Study of Weekly Docetaxel and Cetuximab Chemo radiation for Poor Risk Stage
`III NSCLC. SWOG 0429.
`Principal Investigator: Phase II Trial of combination of OSI-774 (Erlotinib) and Bevacizumab in Never Smokers with
`Stage IIIb and IV Primary Lung Adenocarcinoma. SWOG 0636.
`Principal Investigator: Phase II Trial of Combination of OSI-774 (Erlotinib) and Bevacizumab in Stage IIIB and IV
`Bronchoalveolar Carcinoma and Adenocarcinoma with MAC Features. SWOG 0635
`Principal Investigator: Central Lymphoma Serum Repository Protocol. SWOG 8947.
`
`Principal Investigator: A Phase III Trial of CHOP + Rituxumab vs. CHOP +Iodine-I131-Labelled Monoclonal Anti-B1
`Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma. SWOG 0016.
`Principal Investigator: Evaluation of CHOP Plus Involved Field Radiotherapy followed by Yttrium-90 Ibritumomab
`Tiuxentan for Stage I, IE and non-bulky Stage II and IIE Positive, High Risk Localized Histologies of NHL. SWOG 0313.
`Principal Investigator: Gemcitabine and Cisplatin in Treating Patient with Stage I Non-small cell lung Cancer that was
`Removed by Surgery. SWOG.
`Principal Investigator: Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, prednisone (CHOP)
`and Rituximab plus Bevacizumab for Advanced Stage DLBCL. SWOG 05154.
`Principal Investigator: Gemcitabine and Erlotinib with or without Monoclonal Antibody Therapy in Treating Patients
`with Metastatic Pancreatic Cancer that Cannot be Removed by Surgery. SWOG.
`Principal Investigator: Phase II Study of PXD101 in Relapsed and Refractory Aggressive B-Cell Lymphoma. SWOG
`S0520
`Principal Investigator: Phase III Randomized Study of Four weeks of High Dose IFN-alpha2B in Stage T2b, N0, T3a-bN0
`and T1-4,N1a, 2a, 3 (microscopic) Melanoma. SWOG E1697.
`Principal Investigator: Phase II Trial of BAY 43-9006 in combination with Carboplatin and Paclitaxel in Patients with
`Metastatic Uveal Melanoma. SWOG 0512.
`Principal Investigator: Azacitidine and Gemtuzumab in Treating Older Patients with Previously Untreated AML.
`SWOG.
`Principal Investigator: Myeloma Specimen Repository Protocol. SWOG 0309
`Principal Investigator: Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent
`Capecitabine and Radiotherapy in Extra Hepatic Cholangiocarcinoma. SWOG 0809.
`Principal Investigator: Phase III Randomized Study of Imatinib with or without Bevacizumab in Patients with
`Metastatic or Unresectable GIST. SWOG 0502.
`Principal Investigator: Phase II Study of the Efficacy of Amifostine in Reducing the Incidence and Severity of
`oxaliplatin-induced Neuropathy in Patients with Colorectal Cancer. Sponsored by Medimmune.
`Principal Investigator: A Pilot Phase I Study of Weekly Docetaxel and Cetuximab Chemo Radiation of Poor Risk Small
`Cell Lung Cancer. SWOG 0429.
`Principal Investigator: A Pilot Phase I Study of Weekly docetaxel and Cetuximab Chemo Radiation of Poor Risk Stage III
`NSCLC. SWOG 0429
`Principal Investigator: Collecting and Sorting Blood Samples from Patients with Previously Untreated Non-Hodgkin’s
`Lymphoma. SWOG.
`Principal Investigator: Collecting and Storing Blood and Bone Marrow Samples from Patients with Hematologic
`Cancers. SWOG.
`Principal Investigator: Topotecan with or without Aflibercept in Treating Patients with Extensive Stage Small Cell Lung
`Cancer. SWOG.
`Principal Investigator: Collecting and Storing Blood and Bone Marrow Samples from Patients with Myeloma,
`Waldenstroms Macroglobulinemia, Amyloidosis or Monoclonal Gammopathy of Undetermined significance. SWOG.
`Principal Investigator: Topotecan with or without Aflibercept in Treating Patients with Extensive Stage Small Cell Lung
`Cancer. SWOG.
`Principal Investigator: Osteonecrosis of the Jaw in Patients with Cancer Receiving Zoledronic Acid for Bone. SWOG.
`Principal Investigator: Dasatinib in Treating Patients with Stage IV Breast Cancer that has Spread to the bones. SWOG.
`Principal Investigator: A Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of Treatment with
`OncoVEX-GM-CSF Compared to Subcutaneous Administration of GM-CSF in Previously Treated Melanoma Patients
`with Unresectable Stage 3b, 3c and 4 Disease. Sponsored by BIOVEX.
`Principal Investigator: A Randomized Phase II Trial of BAY 43-9006 with either CCI-779 or R1I5777 (tipifarnib)
`Metastatic Melanoma. SWOG S0438.
`Principal Investigator: Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane
`Induced Neuropathy. SWOG S0715.
`
`7
`
`
`Rigel Exhibit 1006
`Page 7 of 16
`
`

`

`
`10/2010-5/2012
`
`10/2010-5/2012
`
`10/2010-5/2012
`
`10/2010-5/2012
`
`2/2010-5/2012
`
`5/2010-5/2012
`
`10/2010-5/2012
`
`10/2010-5/2012
`
`9/2011-5/2012
`
`11/2011-5/2012
`
`11/2011-5/2012
`
`3/2011-5/2012
`
`11/2011-5/2012
`
`10/2011-5/2012
`
`7/2011-5/2012
`
`6/2011-5/2012
`
`4/2011-5/2012
`
`6/2011-5/2012
`5/2011-5/2012
`
`7/2011-5/2012
`
`9/2011-5/2012
`
`10/2011-5/2012
`
`12/2011-5/2012
`
`Principal Investigator: Phase II Studies of Two Different Schedules of Dasatinib in Bone-Metastasis Predominantly
`Metastatic Breast Cancer. SWOG 0622.
`Principal Investigator: A Randomized Phase III Trial to Test the Strategy of Changing Therapy vs. Maintaining Therapy
`for Metastatic Breast Cancer Patients who have Elevated Circulating Tumor cell Levels at First Follow-up Assessment.
`SWOG 0500.
`Principal Investigator: Phase III Trial of Irinotecan-Based Chemotherapy plus Cetuximab with or without Bevacizumab
`as Second Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with
`either FOLFOX, Optimox or Xelox. SWOG 0600.
`Principal Investigator: CHAARTED: Chemo Hormonal Therapy vs. Androgen Ablation Randomized Trial for Extensive
`Disease in Prostate Cancer. CTSU E3805.
`Principal Investigator: A Randomized, Double-Blind. Phase III Trial Comparing Ipilimumab vs. Placebo Following
`Radiotherapy in Subjects with Castration Resistant Prostate Cancer that have Received Prior Treatment with
`Docetaxel. BMS-CA184-043.
`Principal Investigator: A Phase II Trial of Azacitidine plus Gemtuzumab as Induction and Post-Remission Therapy in
`Patients older than 60 and older with Previously Untreated non-M3 Acute Myeloid Leukemia. SWOG.
`Principal Investigator: Phase II ERCC1 and RRMI-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell
`Lung Cancer. SWOG 0720.
`Principal Investigator: A Randomized Phase II Trial of Weekly Topotecan with and without AVE005 in Patients with
`Platin-Treated Extensive Stage Small Cell Lung Cancer. SWOG 0820.
`Principal Investigator: Treatment Decision Making Based on Blood Levels of Tumor Cells in Women with Metastatic
`Breast Cancer Receiving Chemotherapy. SWOG S0500.
`Principal Investigator: Chemotherapy with or without Bevacizumab in Treating Patients with Stage IB , Stage II or
`Stage IIIa Non-Small Cell Lung Cancer that was Removed by Surgery. SWOG E1505.
`Principal Investigator: Study of Bone Marrow and Blood Samples from Patients with Leukemia or Other
`Hematopoietic cancers. SWOG S9007.
`Principal Investigator: Erlotinib with or without Carboplatin and Paclitaxel in Treating Patients with Stage IIIB or Stage
`IV NSCLC. SWOG S0709.
`Principal Investigator: Gemcitabine after Surgery in Treating Patients with Newly diagnosis or Recurrent Bladder
`Cancer. SWOG S9910.
`Principal Investigator: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in
`Treating Patients with Invasive RxPONDER Breast Cancer. SWOG S1007.
`Principal Investigator: Carboplatin and Paclitaxel with or without Bevacizumab and/or Cetuximab in Treating Patients
`with Stage IV or Recurrent Non-Small Cell Lung Cancer. SWOG S0819.
`Principal Investigator: Radiation Therapy in Treating Women who have undergone Surgery for Ductal Carcinoma in
`Situ for Stage I or Stage II Breast Cancers. SWOG-NSABP-B-39.
`Principal Investigator: Capecitabine, Gemcitabine and Radiation Therapy in Treating Patients with
`Cholangiocarcinoma of the Gallbladder or Bile Duct. SWOG S0808.
`Principal Investigator: R04929097 in Treating Patients with Stage IV Melanoma. SWOG S0933.
`Principal Investigator: Epratuzumab, Cytarabine and Clofarabine in Treating Patients with Relapsed or Refractory
`Acute Lymphoblastic leukemia. SWOG 50910.
`Principal Investigator: Hormone Therapy With or Without Combination Chemotherapy in Treating Women who have
`Undergone Surgery for Node-Negative Breast Cancer (THE TAILORx Trial). SWOG/INTERGOURP CDR0000472066,
`ECOG-PACCT-1
`Principal Investigator: Study of Palifosfamide-tris in Combination with Doxorubicin in Patients with Front-Line
`Metastatic Soft Tissue Sarcoma. Ziopharm IPM30091.
`Principal Investigator: A Phase III Randomized Study of Adjuvant Ipilimumab anti-CTLA4-therapy vs. High Dose IFN for
`Resected High Risk Melanoma. CTSU E1609
`Principal Investigator: A Phase III blinded study of immediate post-TURBT Instillation of Gemcitabine vs. Saline in
`Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Blad